UCB And Biogen Lifted By Promising Late-Stage Lupus Data

 
• By Kevin Grogan

The clinical road has been pretty rocky for dapirolizumab pegol but a Phase III win is good news for the limited armamentarium of innovative treatments for lupus and a boost for Biogen’s hopes to expand its presence in immunology.

Medecine concept - Blackboard with text "Lupus", book, pills and stethoscope on blue wooden background
• Source: Shutterstock

More from Immunological

More from Therapy Areas